Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate for sedation during endoscopic hemostasis of variceal bleeding
NCT05554965Phase 4Unknown
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of remimazolam in Esophageal variceal hemorrhage (EVH) and gastric varices (2 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Sedation scores at 48 hours. Status: unknown.
02
Drugs
remimazolam
03
Conditions
Esophageal variceal hemorrhage (EVH)gastric varices
Beyond the preview
Go deeper on NCT05554965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554965.